JOURNAL OF THORACIC DISEASE, cilt.6, sa.6, ss.778-784, 2014 (SCI-Expanded)
Background: The impacts of epidermal growth factor receptor (EGFR) immunoexpression and RAS immunoexpression on the survival and prognosis of lung adenocarcinoma patients are debated in the literature.